X

Articles

04Jan

FDA Updates Emergency Use Authorization for COVID-19 Convalescent Plasma

0 Comments | | Return |

On December 28, 2021, the FDA updated the emergency use authorization  (EUA) for COVID-19 convalescent plasma.  The update limits the authorization to the use of COVID-19 convalescent plasma with high titers of anti -SARS-CoV-2 antibodies for the treatment of COVID-19 in patients with immunosuppressive disease or who are receiving immunosuppressive treatment.  Additionally, to help assure the manufacture of high titer COVID-19 convalescent plasma, the revisions to the EUA define acceptable tests and increase qualifying result cutoffs to be used for manufacturing COVID-19 convalescent plasma with high titers of anti-SARS-CoV-2 antibodies.

We are currently evaluating our options to determine if we can provide additional testing services using one of the newly defined assays. Please reach out to your customer service manager if your organization is considering CCP testing under the updated guidelines. 

 

 

 

Related

FDA announces withdrawal of Guidance for ZIKV Testing

We are informing you that the FDA has announced their withdrawal of Guidance for ZIKV Testing. In th...

Read More >

Phoenix Laboratory Transition to the VISION Analyzer

On September 14, 2020, our Phoenix laboratory began performing a portion of our alternate donor anti...

Read More >

Exhibiting at AABB Annual Meeting- Booth 1038

We sincerely hope to see you at this year’s AABB Annual Meeting in Boston, MA on October 12-16...

Read More >

The Reentry Changes Q & A document is now available

The Q & A document from the Reentry Changes Webinar hosted on 06/06/18 has been posted in the Wh...

Read More >

CTS Tampa Implementation date change for Ultrio Elite

CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex...

Read More >

Join us for a Babesia webinar!

As communicated on January 21, 2020, CTS will implement the licensed Grifols Babesia test for sample...

Read More >

Subscribe here to receive CTS updates!

Name